PhaseBio gets FDA nod to begin Covid-19 trial with VIP receptor agonist PB1046

PhaseBio has secured FDA authorisation to begin Covid-19 trial with VIP receptor agonist PB1046. (Credit: PIRO4D from Pixabay)